EUVIMEDEUVIMED entdecken
Crossref

Liquiritigenin attenuates thrombosis by inhibiting P2Y12R-mediated Src/PLCγ2 signaling and cytoplasmic Ca2+ mobilization in platelets

Linhui Cheng, Tao Yu, Hanrong Xue, Shuangdi Xiang

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2025.157553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Linhui Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi University of Chinese Medicine, Nanchang,330000, China; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanj…. Hauptthemen laut MEDLINE: Thrombosis, Blood Platelets, Flavanones, Receptors, Purinergic P2Y12. Die Arbeit nennt 54 Literaturangaben. Gefördert von: State Administration of Traditional Chinese Medicine of the People's Republic of China, Jiangxi Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiovascular and cerebrovascular diseases are the leading causes of death worldwide. Pathological thrombosis is a major underlying mechanism, where excessive platelet activation triggered by vascular injury constitutes a key event. Liquiritigenin, a key flavonoid constituent of Glycyrrhiza glabra l., has been reported to possess diverse pharmacological properties, including anti-inflammatory, anti-tumor, neuroprotective, and cardiovascular protective effects. However, its specific role in platelet activation remains unclear. PURPOSE: This study aims to explore the mechanism through which liquiritigenin inhibits platelet activation to attenuate thrombosis. METHODS: The inhibitory effect of Liquiritigenin on platelet activation was evaluated using thrombin, ADP, and collagen as agonists. A co-culture system of platelets with human umbilical vein endothelial cells (HUVECs) on a collagen-coated surface was established to simulate platelet adhesion to vascular endothelia and subendothelial matrix under flow conditions. Flow cytometry, transmission electron microscopy, fluorescence labeling, and Western blotting were employed to assess P-selectin (CD62P) expression, dense granule secretion, and platelet adhesion following activation. The effects of Liquiritigenin on the Src/PLCγ2 signaling pathway, cytoplasmic Ca²⁺ mobilization, and the interaction between P2Y12R and the guanine nucleotide-binding protein Gi subunit alpha-1 (Gαi1) were further investigated. Additionally, integrated analysis of multiple single-cell transcriptome datasets was performed to identify cell types interacting with activated platelets in heart and lung tissues. The anti-thrombotic efficacy of liquiritigenin was evaluated in two in vivo models: acute pulmonary thromboembolism (APE) and coronary microvascular dysfunction (CMD). RESULTS: Liquiritigenin demonstrated a more potent inhibitory effect on ADP-activated platelets than on those activated by thrombin or collagen. It significantly suppressed ADP-induced P-selectin expression, dense granule secretion, and platelet adhesion to HUVECs. Furthermore, Liquiritigenin inhibited the ADP-triggered Src/PLCγ2 signaling pathway, reduced cytoplasmic Ca²⁺ mobilization, and attenuated the interaction between P2Y12R and Gαi1. Molecular modeling indicated that Liquiritigenin binds to key P2Y12R residues-LYS179, CYS97, and ASN191-which are also involved in ADP binding. In animal models, Liquiritigenin administration significantly reduced thrombus formation in the lung tissue of APE and within the coronary micro vessels of CMD model animals. CONCLUSION: The findings indicate that Liquiritigenin inhibits platelet activation by targeting P2Y12R. This action disrupts the Src/PLCγ2 signaling pathway and subsequently reduces cytoplasmic calcium mobilization. These results suggest that Liquiritigenin may have therapeutic potential for the treatment of thrombotic diseases associated with platelet activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombosisBlood PlateletsFlavanonesReceptors, Purinergic P2Y12HumansAnimalsHuman Umbilical Vein Endothelial CellsCalciumPhospholipase C gammaSignal TransductionPlatelet Activationsrc-Family KinasesMiceMaleGlycyrrhizaCoculture Techniques

Stichwörter der Autor:innen

Ca(2+)LiquiritigeninPlatelet activation;P2Y12RSrc/PLCγ2 signaling pathwayThrombosis

Substanzen

FlavanonesliquiritigeninReceptors, Purinergic P2Y12CalciumPhospholipase C gammasrc-Family Kinases

Autor:innen und Institutionen

  • Jiangxi University of Chinese Medicine, Nanchang,330000, China; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China. Electronic address: hbcyxsd94@163.com.
  • Jiangxi University of Chinese Medicine, Nanchang,330000, China. Electronic address: 935478487@qq.com.
  • Jiangxi University of Chinese Medicine, Nanchang,330000, China. Electronic address: xuehanrong99@163.com.
  • Jiangxi University of Chinese Medicine, Nanchang,330000, China. Electronic address: hbcylyj96@163.com.

Förderung

  • State Administration of Traditional Chinese Medicine of the People's Republic of China
  • Jiangxi Provincial Natural Science Foundation

Zitieren

APA

Cheng, L., Yu, T., Xue, H., & Xiang, S. (2025). Liquiritigenin attenuates thrombosis by inhibiting P2Y12R-mediated Src/PLCγ2 signaling and cytoplasmic Ca2+ mobilization in platelets. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157553

Vancouver

Cheng L, Yu T, Xue H, Xiang S. Liquiritigenin attenuates thrombosis by inhibiting P2Y12R-mediated Src/PLCγ2 signaling and cytoplasmic Ca2+ mobilization in platelets. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157553

BibTeX
@article{Cheng2025,
  author = {Cheng, Linhui and Yu, Tao and Xue, Hanrong and Xiang, Shuangdi},
  title = {Liquiritigenin attenuates thrombosis by inhibiting P2Y12R-mediated Src/PLCγ2 signaling and cytoplasmic Ca2+ mobilization in platelets},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2025.157553}
}
Kostenlos starten →